Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2010 1
2013 3
2014 3
2015 6
2016 6
2017 3
2018 5
2019 18
2020 8
2021 10
2022 10
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Leveraging Off-Target Reads in Panel Sequencing for Homologous Recombination Repair Deficiency Screening in Tumor.
Ball M, Ourailidis I, Kluck K, Menzel M, Kirchner M, Allgäuer M, Tay TKY, Schnecko F, Volckmar AL, Goldschmid H, Neuman O, Fröhling S, Schirmacher P, Budczies J, Stenzinger A, Kazdal D. Ball M, et al. Among authors: allgauer m. J Mol Diagn. 2024 Mar 22:S1525-1578(24)00060-6. doi: 10.1016/j.jmoldx.2024.02.008. Online ahead of print. J Mol Diagn. 2024. PMID: 38522840 Free article.
The pregnancy-associated protein glycodelin as a potential sex-specific target for resistance to immunotherapy in non-small cell lung cancer.
Richtmann S, Marwitz S, Muley T, Koistinen H, Christopoulos P, Thomas M, Kazdal D, Allgäuer M, Winter H, Goldmann T, Meister M, Klingmüller U, Schneider MA. Richtmann S, et al. Among authors: allgauer m. Transl Res. 2024 Mar 13:S1931-5244(24)00036-7. doi: 10.1016/j.trsl.2024.02.007. Online ahead of print. Transl Res. 2024. PMID: 38490536 Free article.
Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors.
Menzel M, Kirchner M, Kluck K, Ball M, Beck S, Allgäuer M, Assmann C, Schnorbach J, Volckmar AL, Tay TKY, Goldschmid H, Tan DS, Thomas M, Kazdal D, Budczies J, Stenzinger A, Christopoulos P. Menzel M, et al. Among authors: allgauer m. J Pathol Clin Res. 2024 Mar;10(2):e354. doi: 10.1002/cjp2.354. J Pathol Clin Res. 2024. PMID: 38284983 Free PMC article.
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.
Blasi M, Kuon J, Lüders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, Kazdal D, Falkenstern-Ge RF, Hackanson B, Dintner S, Faehling M, Kirchner M, Volckmar AL, Kopp HG, Allgäuer M, Grohé C, Tufman A, Reck M, Frost N, Stenzinger A, Thomas M, Christopoulos P. Blasi M, et al. Among authors: allgauer m. Eur J Cancer. 2024 Mar;199:113556. doi: 10.1016/j.ejca.2024.113556. Epub 2024 Jan 17. Eur J Cancer. 2024. PMID: 38271745 Free article.
Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients.
Menzel M, Ossowski S, Kral S, Metzger P, Horak P, Marienfeld R, Boerries M, Wolter S, Ball M, Neumann O, Armeanu-Ebinger S, Schroeder C, Matysiak U, Goldschmid H, Schipperges V, Fürstberger A, Allgäuer M, Eberhardt T, Niewöhner J, Blaumeiser A, Ploeger C, Haack TB, Tay TKY, Kelemen O, Pauli T, Kirchner M, Kluck K, Ott A, Renner M, Admard J, Gschwind A, Lassmann S, Kestler H, Fend F, Illert AL, Werner M, Möller P, Seufferlein TTW, Malek N, Schirmacher P, Fröhling S, Kazdal D, Budczies J, Stenzinger A. Menzel M, et al. Among authors: allgauer m. NPJ Precis Oncol. 2023 Oct 20;7(1):106. doi: 10.1038/s41698-023-00457-x. NPJ Precis Oncol. 2023. PMID: 37864096 Free PMC article.
Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.
Seker-Cin H, Tay TKY, Kazdal D, Kluck K, Ball M, Neumann O, Winter H, Herth F, Heußel CP, Savai R, Schirmacher P, Thomas M, Budczies J, Allgäuer M, Christopoulos P, Stenzinger A, Volckmar AL. Seker-Cin H, et al. Among authors: allgauer m. Lung Cancer. 2023 Oct;184:107317. doi: 10.1016/j.lungcan.2023.107317. Epub 2023 Jul 27. Lung Cancer. 2023. PMID: 37586177
Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas.
Goldschmid H, Kluck K, Ball M, Kirchner M, Allgäuer M, Winter H, Herth F, Heußel CP, Pullamsetti SS, Savai R, Yong TTK, Schirmacher P, Peters S, Thomas M, Christopoulos P, Budczies J, Stenzinger A, Kazdal D. Goldschmid H, et al. Among authors: allgauer m. Lung Cancer. 2023 Jun;180:107212. doi: 10.1016/j.lungcan.2023.107212. Epub 2023 Apr 23. Lung Cancer. 2023. PMID: 37141769
Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial.
Strnad V, Polgár C, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, Łyczek J, Guinot JL, Gutierrez Miguelez C, Slampa P, Allgäuer M, Lössl K, Polat B, Fietkau R, Schlamann A, Resch A, Kulik A, Arribas L, Niehoff P, Guedea F, Dunst J, Gall C, Uter W; Groupe Européen de Curiethérapie and European Society for Radiotherapy and Oncology. Strnad V, et al. Among authors: allgauer m. Lancet Oncol. 2023 Mar;24(3):262-272. doi: 10.1016/S1470-2045(23)00018-9. Epub 2023 Feb 1. Lancet Oncol. 2023. PMID: 36738756 Clinical Trial.
73 results